ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers? [In the Spotlight]

Summary: ERK inhibitors have enormous therapeutic potential against tumors that are BRAF mutant, BRAF–MEK inhibitor resistant, or RAS mutant. In this issue of Cancer Discovery, Sullivan and colleagues report on the first-in-human dose-escalation study of the ERK inhibitor ulixertinib, which they show to be well tolerated with clinical activity against a wide range of tumor types. Cancer Discov; 8(2); 140–2. ©2018 AACR.

See related article by Sullivan et al., p. 184.

from Cancer via ola Kala on Inoreader http://ift.tt/2nOsxvf
via IFTTT